Nicotinamide Mononucleotide (NMN): Difference between revisions

Nicotinamide Mononucleotide (NMN) (view source)

654 bytes removed , 31 October 2023

2,851

edits

@@ Line 143: / Line 143: @@
 !Outcome
 |-
-|Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men {{#pmid:31685720|pmid31685720|url=https://www.jstage.jst.go.jp/article/endocrj/67/2/67_EJ19-0313/_html/-char/en}}
+|{{#pmid:31685720|#pmid_text}}
 |
 * singe admission of up to 500 mg
@@ Line 153: / Line 153: @@
 * admission was safe and well-tolerated
 |-
-|Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women <ref name="pmid33888596"/>
+|{{#pmid:33888596|#pmid_text}}
 |[[RCT]], 10 weeks
 * placebo (n=12)
@@ Line 165: / Line 165: @@
 * improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss
 |-
-|Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study {{#pmid:34238308|pmid34238308}}
+|{{#pmid:34238308|#pmid_text}}
 |[[RCT]], 6 weeks
 * placebo (n=12)
@@ Line 179: / Line 179: @@
 * The improvement is muscle, not cardiac, related.
 |-
-|The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial {{#pmid:36482258|pmid36482258}}
+| {{#pmid:36482258|#pmid_text}}
 |[[RCT]], 8.5 weeks (60 days)